No Data
IMMUNEONCO-B (01541.HK): Listed in Hong Kong has been granted listing approval by the Stock Exchange for full circulation.
Gelonghui reported on April 24 that IMMUNEONCO-B (01541.HK) announced that the company has applied to the Listing Committee of the Stock Exchange for approval to list and trade 14,114,006 shares of H shares ("Converted H Shares", the maximum number of non-listed shares that can be converted according to the filing notice) on the Main Board of the Stock Exchange. The company is pleased to announce that the Stock Exchange has granted approval for listing on April 24, 2025.
[Brokerage Focus] Guoyuan Securities (Hong Kong): The impact of Pharmaceutical tariffs is limited, and the outlook for Innovative Drugs going abroad is bullish.
Jinwu Finance | Guoyuan (Hong Kong) released a Research Report indicating that the US Secretary of Commerce, Raimondo, recently stated that tariffs on pharmaceuticals would be imposed within 1 to 2 months. However, the Institutions believe that there is uncertainty regarding the imposition of pharmaceutical tariffs, and it is merely a disturbance to the pharmaceutical Industry, with no impact on the prospects for Innovative Drugs going abroad. First, Guoyuan (Hong Kong) points out that the imposition of pharmaceutical tariffs by the USA has been repeated multiple times recently, and there is uncertainty regarding whether tariffs will actually be imposed. Even if imposed, the impact on Hong Kong-listed pharmaceutical companies would be minimal. Pharmaceutical companies only have some Active Pharmaceutical Ingredients and a small number of generic drugs sold in the USA, and the imposition, even if it occurs, would only be a disturbance to the pharmaceutical Industry.
Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%. The impact of China Securities Co.,Ltd.'s tariff policy on the Industry Chain of pharmaceuticals still has uncertainties.
Jinwu Finance | Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%, HBM HOLDINGS-B (02142) down 25.43%, CUTIA-B (02487) down 25.13%, Yiming Angke-B (01541) down 24.73%, CSTONE PHARMA-B (02616) down 24.68%, LAEKNA-B (02105) down 24.38%, WUXI BIO (02269) down 24.02%, JACOBIO-B (01167) down 23.72%, and WUXI XDC (02268) down 23.45%. According to multiple sources.
Hong Kong Stock Announcement | HENLIUS: The phase 3 clinical study of the recombinant anti-VEGF humanized monoclonal antibody injection HLX04-O for the treatment of wet age-related macular degeneration (wAMD) has reached its primary study endpoint.
CHINA NEWCITY (01321) collaborates with CITIC Capital to establish a joint platform to explore new opportunities in urban renewal and distressed asset investment; IMMUNEONCO-B (01541) has had its application for clinical trials of IMC-003/IMM72 for treating pulmonary arterial hypertension (PAH) accepted by the National Medical Products Administration.
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Nmpa Accepted Application for Clinical Trial of Imc-003/Imm72
IMMUNEONCO-B (01541) has received acceptance from the National Medical Products Administration for the clinical trial application of IMC-003/IMM72 for the treatment of pulmonary arterial hypertension (PAH).
IMMUNEONCO-B (01541) announced that the National Medical Products Administration of the People's Republic of China has received...
